– Data being presented show long-term benefits of Bylvay in children with PFIC – – First potential non-invasive treatment option that could transform the treatment paradigm – – Observed long-term improvements in total bilirubin, growth, and sleep measures – – Data validates the PRUCISION © ObsRO

BOSTON , May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of fireside chats at both the 2021 Jefferies Virtual

– Bylvay has the potential to become first approved drug to treat all forms of PFIC – – CHMP opinion is based on the PEDFIC Phase 3 studies – – PEDFIC 1 met the bile acid (P=0.003) and pruritus (P=0.004) primary endpoints, with a diarrhea rate of 10% vs 5% placebo – – Integrated EU commercial,

- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC - - Data showing long-term treatment benefits of Bylvay™   (odevixibat ) , including improvements in total bilirubin, growth, and sleep – BOSTON , May 19, 2021 (GLOBE

BOSTON , May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.

– Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU– – Completed global commercial agreements for two key top ten markets – – ASSERT & BOLD Phase 3 studies enrolling and on track – – Advanced novel MOA ASBTi A3907 into Phase 1 study – – Recent CTO

Conference call and webcast to be held at 10:00 a.m. ET BOSTON , April 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and

– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug development, manufacturing, quality and supply chain – BOSTON , April 13, 2021 (GLOBE NEWSWIRE) -- Albireo

BOSTON , April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the upcoming Needham 20th Annual Healthcare Conference on April 12-15 .

– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing odevixibat for PFIC, currently no plans for FDA advisory committee meeting – – Achievement of important